CD8A and cancer: Cyclic FMD is safe, feasible, and potentially beneficial for patients receiving concomitant cancer treatments.FMD can enrich response-associated immune signatures, reducing immunosuppressive cell populations and improving immunosurveillance (greater amounts/activation of CD8+ TCs and NKCs).